Sarepta Therapeutics, Inc. or ADMA Biologics, Inc.: Who Leads in Yearly Revenue?

Sarepta's Revenue Dominance Over ADMA in Biotech

__timestampADMA Biologics, Inc.Sarepta Therapeutics, Inc.
Wednesday, January 1, 201459155459757000
Thursday, January 1, 201571776331253000
Friday, January 1, 2016106610375421000
Sunday, January 1, 201722760560154584000
Monday, January 1, 201816985290301034000
Tuesday, January 1, 201929349083380833000
Wednesday, January 1, 202042219783540099000
Friday, January 1, 202180942625701887000
Saturday, January 1, 2022154079692933013000
Sunday, January 1, 20232582149991243336000
Loading chart...

In pursuit of knowledge

Biotech Revenue Race: ADMA vs. Sarepta

In the dynamic world of biotechnology, revenue growth is a key indicator of a company's success and market influence. Over the past decade, Sarepta Therapeutics, Inc. has consistently outpaced ADMA Biologics, Inc. in annual revenue. Starting in 2014, Sarepta's revenue was nearly double that of ADMA, and by 2023, it had surged to approximately five times ADMA's revenue. This impressive growth trajectory highlights Sarepta's strategic advancements and market penetration.

Revenue Trends Over the Years

From 2014 to 2023, Sarepta's revenue increased by over 12,000%, while ADMA saw a growth of around 4,300%. This stark contrast underscores Sarepta's dominant position in the biotech sector. As both companies continue to innovate, investors and industry watchers will be keenly observing how these revenue trends evolve in the coming years.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025